Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Studies reveal that obese people are at greater risk for developing Alzheimer's disease

Obesity is on a rampage, with the World Health Organization pegging the numbers at more than 300 million worldwide, with a billion more overweight. With obesity comes the increased risk for cardiovascular disease, Type II diabetes, and hypertension.

25 Aug 2009

MEDRAD and USF sign research agreement to study FDG administration effect on the workflow for PET imaging procedures

...

25 Aug 2009

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Portola Pharmaceuticals, Inc. today announced two oral presentations at the European Society of Cardiology (ESC) Congress 2009 in Barcelona, Spain, that will feature its investigational antiplatelet drug elinogrel, a P2Y12 ADP receptor antagonist that is currently in Phase II clinical development with Novartis, Portola's development and commercialization partner.

25 Aug 2009

New study reveals that mild glucose intolerance in pregnancy may relate to risk of heart disease

Mild glucose intolerance in pregnancy may be an early identifier of women who are at increased risk of heart disease in the future, found a new study http://www.cmaj.ca/press/cmaj090569.pdf published in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

25 Aug 2009

Research reveals the life-long detrimental impact of maternal smoking during pregnancy

A new study by researchers at the Keck School of Medicine of the University of Southern California (USC) has found that the life-long effects of maternal smoking during pregnancy may occur through specific changes in DNA patterns.

25 Aug 2009

Studies reveal that obese men are at increased risk for erectile dysfunction

Obese men are at increased risk for erectile dysfunction (ED), likely caused by atherosclerosis-related hypertension and cardiovascular disease, as well as hormonal changes associated with obesity, as described in a timely article published in Obesity and Weight Management, a journalzine published by Mary Ann Liebert, Inc.

25 Aug 2009

Fatty liver associated with metabolic problems

New findings from nutrition researchers at Washington University School of Medicine in St. Louis suggest that it's not whether body fat is stored in the belly that affects metabolic risk factors for diabetes, high blood triglycerides and cardiovascular disease, but whether it collects in the liver.

25 Aug 2009

Diabetics can reduce the risk of cardiovascular disease by increasing vitamin D levels

Low levels of vitamin D are known to nearly double the risk of cardiovascular disease in patients with diabetes, and researchers at Washington University School of Medicine in St. Louis now think they know why.

24 Aug 2009

Microbiologists discover new therapies for human respiratory syncytial virus and influenza A virus

A cellular molecule that not only can sense two common respiratory viruses but also can direct cells to mount a defense has been identified by microbiologists at The University of Texas Health Science Center at San Antonio.

24 Aug 2009

Cortex Pharmaceuticals receives delisting notification from NYSE Amex

Cortex Pharmaceuticals, Inc. (NYSE Amex (COR)) reported that it has received a delisting notification from the NYSE Amex LLC indicating that it has not accepted the Company’s plan to regain compliance with the Exchange’s continued listing standards, as submitted by the Company in June.

21 Aug 2009

Takeda Canada reacquires commercial rights for an oral type 2 diabetic treatment drug

Takeda Canada, Inc. announced that it has reacquired the Canadian commercial rights to ACTOS(R) (pioglitazone HCl), an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda, the discoverer of ACTOS, licensed the drug to Lilly as part of a worldwide agreement in 1999.

21 Aug 2009

New website launched to determine sleep disorder

Nearly 20 million Americans suffer from sleep apnea, a serious health condition that has been linked to increased risks for obesity and weight gain, heart attack, stroke, high blood pressure, asthma and depression. Sleep apnea has also been cited by experts as the number one cause of car accidents. Ninety-five percent of sleep apnea cases go undiagnosed, putting the health of millions of Americans at risk.

21 Aug 2009

Research attributes accumulation of belly fat to change in hormone balance during menopause transition

In middle-aged women, visceral fat, more commonly called belly fat, is known to be a significant risk factor for cardiovascular disease, but what causes visceral fat to accumulate?

21 Aug 2009

Software suite for comprehensive analysis of cardiac safety released by NewCardio

NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, today announced that the Company has formally launched its lead product, QTinno(TM), a software suite that provides an automated, comprehensive analysis of cardiac safety for the pharmaceutical industry.

20 Aug 2009

Consumer-friendly "finger stick" blood test to detect cardiovascular disease is broadly available now

A new blood test, measuring the level of omega-3 fatty acids in red blood cells, is now broadly available for the first time to the public everywhere as a consumer-friendly, at-home "finger stick" test. While scientists have long known of the benefits of fish and fish oil for overall heart health, over the past decade research has proven that the omega-3 fatty acids found in fish dramatically reduce one's risk for cardiovascular disease. Further, recent research indicates that omega-3 levels may be among the best predictors of future coronary heart disease - providing much stronger correlations to the risk of sudden cardiac death than traditional indicators, including HDL and LDL cholesterol.

20 Aug 2009

Researcher of LA BioMed elected to distinguished fellow status of SVS

Carlos E. Donayre, MD, a researcher at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), has been elected to distinguished fellow status of the Society for Vascular Surgery- (SVS).

20 Aug 2009

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

19 Aug 2009

Researchers find connection between eye disease and arginase

Elevated levels of the enzyme arginase contribute to vascular eye damage and Medical College of Georgia researchers say therapies to normalize its levels could halt progression of potentially blinding diseases such as diabetic retinopathy.

19 Aug 2009

Bioheart's executive management team strengthened by the inclusion of board members

Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.

19 Aug 2009

Beveragette Ventures launches all-natural beverage to minimize common PMS and menopause symptoms

Seattle-based, women-owned, Beveragette Ventures LLC, developers of the innovative, wellness beverage line, GEM, announced today the launch of Keep it Cool(TM), an all-natural, low-calorie, peach-pineapple flavored beverage, with clinically proven ingredients to minimize the many symptoms of menopause; hot flashes, night sweats, mood swings, irritability and sleeplessness.

19 Aug 2009

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Studies reveal that obese people are at greater risk for developing Alzheimer's disease

MEDRAD and USF sign research agreement to study FDG administration effect on the workflow for PET imaging procedures

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

New study reveals that mild glucose intolerance in pregnancy may relate to risk of heart disease

Research reveals the life-long detrimental impact of maternal smoking during pregnancy

Studies reveal that obese men are at increased risk for erectile dysfunction

Fatty liver associated with metabolic problems

Diabetics can reduce the risk of cardiovascular disease by increasing vitamin D levels

Microbiologists discover new therapies for human respiratory syncytial virus and influenza A virus

Cortex Pharmaceuticals receives delisting notification from NYSE Amex

Takeda Canada reacquires commercial rights for an oral type 2 diabetic treatment drug

New website launched to determine sleep disorder

Research attributes accumulation of belly fat to change in hormone balance during menopause transition

Software suite for comprehensive analysis of cardiac safety released by NewCardio

Consumer-friendly "finger stick" blood test to detect cardiovascular disease is broadly available now

Researcher of LA BioMed elected to distinguished fellow status of SVS

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Researchers find connection between eye disease and arginase

Bioheart's executive management team strengthened by the inclusion of board members

Beveragette Ventures launches all-natural beverage to minimize common PMS and menopause symptoms

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Newsletters you may be interested in